Abstract Number: 162 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Background/Purpose: Gout patients have a high frequency of metabolic syndrome (MS), a disorder known to be associated with hyperinsulinemia. The latter condition augments proximal tubular…Abstract Number: 2043 • 2012 ACR/ARHP Annual Meeting
Documentation of Improvement Over 2 Months in Osteoarthritis, Systemic Lupus Erythematosus, Spondyloarthropathy and Gout Similarly to Rheumatoid Arthritis According to Function, Pain, Patient Global Estimate and RAPID3 On a Multidimensional Health Assessment Questionnaire (MDHAQ)
Background/Purpose: The health assessment questionnaire (HAQ) and multidimensional HAQ (MDHAQ) were developed initially to assess patients with rheumatoid arthritis (RA). The most feasible method to…Abstract Number: 1632 • 2012 ACR/ARHP Annual Meeting
Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties
Background/Purpose: In most patients with gout, elevated serum urate is linked to excess uric acid reabsoprtion in the proximal renal tubule by anion transporters/exchangers, including…Abstract Number: 163 • 2012 ACR/ARHP Annual Meeting
Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Background/Purpose: Higher serum uric acid levels in gout patients have been associated with an increased frequency and risk of gout flares and greater subsequent healthcare…Abstract Number: 2045 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns and Monitoring of Serum Uric Acid Levels in a Large Cohort of Gout Patients in the United States: Is There Room for Improvement?
Background/Purpose: Currently, there are no guidelines in the United States on monitoring serum uric acid (sUA) levels in gout and gout treatment patterns. However, there…Abstract Number: 1633 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Background/Purpose: Ulodesine (BCX4208) is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on therapy for the chronic management of hyperuricemia in…Abstract Number: 139 • 2012 ACR/ARHP Annual Meeting
Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout
Background/Purpose: The key to effective long-term management of gout is sustained reduction of serum urate (SU) Methods: Patients with gout and a SU >0.36mmol/L…Abstract Number: 2037 • 2012 ACR/ARHP Annual Meeting
Poor Quality of Gout Care Is Strongly Associated with Higher Gout-Related Health Care Utilization
Background/Purpose: Proponents of improving quality of gout care have suggested various gout quality indicators, but no study to date has shown the link between…Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]Abstract Number: 140 • 2012 ACR/ARHP Annual Meeting
Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy
Background/Purpose: Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. The purpose of this study is to describe physician, patient and treatment…
- « Previous Page
- 1
- …
- 43
- 44
- 45